Initial Experience of Drug-Eluting Bead-Transcatheter Arterial Chemoembolization After Lipiodol-Based Transcatheter Arterial Chemoembolization Failure for Patients with Advanced Hepatocellular Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Zhang ZM, Lai EC, Zhang C, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg. 2015;20:8–16. doi:10.1016/j.ijsu.2015.05.00926026424
   PubMed Web of Science ®Google Scholar
• Chequi D, Laurent A, Mocellin N, et al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg. 2009;250:738–746. doi:10.1097/SLA.0b013e3181bd582b19801927
   PubMed Web of Science ®Google Scholar
• Kishore S, Friedman T, Madoff DC. Update on embolization therapies for hepatocellular carcinoma. Curr Oncol Rep. 2017;19(6):40. doi:10.1007/s11912-017-0597-228421483
   PubMed Web of Science ®Google Scholar
• Forner A, Gilabert M, Bruix J, et al. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11(9):525–535. doi:10.1038/nrclinonc.2014.12225091611
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–1739. doi:10.1016/S0140-6736(02)08649-X12049862
   PubMed Web of Science ®Google Scholar
• Lo C, Ngan H, Tso W, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–1171. doi:10.1053/jhep.2002.3315611981766
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng A-L, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–370.28620797
   PubMed Web of Science ®Google Scholar
• Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24:2074–2081. doi:10.1158/1078-0432.CCR-17-289929420221
   PubMed Web of Science ®Google Scholar
• Lucatelli P, Argirò R, Bascetta S, et al. Single injection dual phase CBCT technique ameliorates results of transarterial chemoembolization for hepatocellular cancer. Transl Gastroenterol Hepatol. 2017;2:83. doi:10.21037/tgh.2017.10.0329167830
   PubMed Web of Science ®Google Scholar
• Geschwind JF, Kudo M, Marrero JA, et al. TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON. Radiology. 2016;279(2):150667. doi:10.1148/radiol.2015150667
   Web of Science ®Google Scholar
• Lewis AL, Gonzalez MV, Lloyd AW, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol. 2006;17(2):335–342. doi:10.1097/01.RVI.0000195323.46152.B316517780
   PubMed Web of Science ®Google Scholar
• Murata Y, Hiramatsu K, Yoshida Y, et al. Reactivation of intraabdominal tuberculous lymphadenopathy after drug-eluting beads transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma. Clin J Gastroenterol. 2019;12(1):76–81. doi:10.1007/s12328-018-0894-930141183
   PubMed Web of Science ®Google Scholar
• Isfort P, Rauen P, Na HS, et al. Does drug-eluting bead tace enhance the local effect of ire imaging and histopathological evaluation in a porcine model. Cardiovasc Intervent Radiol. 2019;42(6):880–885. doi:10.1007/s00270-019-02181-130737544
   PubMed Web of Science ®Google Scholar
• Li H, Wu F, Duan M, et al. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history. Medicine. 2019;98(21):e15314.31124925
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhou J, Zhu DD, et al. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study. Clin Transl Oncol. 2019;21:167–177. doi:10.1007/s12094-018-1902-830003530
   PubMed Web of Science ®Google Scholar
• Bargellini I, Lorenzoni V, Lorenzoni G, et al. Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naive patients: a propensity score matching analysis. Eur Radiol. 2021;31:7512–7522.33871708
   PubMed Web of Science ®Google Scholar
• Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87(Suppl 1):22–31. doi:10.1159/00036814225427730
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(01):52–60. doi:10.1055/s-0030-124713220175033
   PubMed Web of Science ®Google Scholar
• Klompenhouwer EG, Dresen RC, Verslype C, et al. Transarterial radioembolization following chemoembolization for unresectable hepatocellular carcinoma: response based on apparent diffusion coefficient change is an independent predictor for survival. Cardiovasc Intervent Radiol. 2018;41(11):1716–1726. doi:10.1007/s00270-018-1991-329872894
   PubMed Web of Science ®Google Scholar
• Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art. World J Gastroenterol. 2018;24(2):161–169. doi:10.3748/wjg.v24.i2.16129375202
   PubMed Web of Science ®Google Scholar
• Song JE, Kim DY. Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol. 2017;9(18):808–814. doi:10.4254/wjh.v9.i18.80828706579
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;31:645–653.
   Google Scholar
• Zhang ZS, Li HZ, Ma C, et al. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety. BMC Cancer. 2019;19. doi:10.1186/s12885-019-6386-6
   Web of Science ®Google Scholar
• Kloth C, Thaiss WM, Kärgel R, et al. Evaluation of texture analysis parameter for response prediction in patients with hepatocellular carcinoma undergoing drug-eluting bead transarterial chemoembolization (DEB-TACE) using biphasic contrast-enhanced CT image data: correlation with liver perfusion CT. Acad Radiol. 2017;24(11):1352. doi:10.1016/j.acra.2017.05.00628652049
   PubMed Web of Science ®Google Scholar
• Fournier E, Saidak Z, Drullion C, et al. Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib. Cancer Lett. 2016;370(2):242–249. doi:10.1016/j.canlet.2015.10.03226546044
   PubMed Web of Science ®Google Scholar
• Zhu M, Li W, Guo J, et al. Alpha fetoprotein antagonises benzyl isothiocyanate inhibition of the malignant behaviors of hepatocellular carcinoma cells. Oncotarget. 2016;7(46):75749–75762. doi:10.18632/oncotarget.1240727716619
   PubMedGoogle Scholar
• Malagari K, Pomoni M, Spyridopoulos TN, et al. Safety profile of sequential transcatheter chemoembolization with DC Bead: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol. 2011;34(4):774–785. doi:10.1007/s00270-010-0044-321184228
   PubMed Web of Science ®Google Scholar
• Luz JH, Luz PM, Martin HS, et al. DEB TACE for intermediate and advanced HCC-initial experience in a Brazilian cancer center. Cancer Imaging. 2017;17(1):5–8. doi:10.1186/s40644-017-0108-628166821
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Tajiri K, Murayama A, et al. Drug-eluting bead-transcatheter arterial chemoembolization for advanced hepatocellular carcinoma refractory to conventional lipiodol-based transcatheter arterial chemoembolization. J Hepatocell Carcinoma. 2020;7:181–189. doi:10.2147/JHC.S27392933117752
   PubMed Web of Science ®Google Scholar